Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Synthetic MR AB's EBITDA for the
three
months ended in Mar. 2026 was kr-2.94 Mil. Synthetic MR AB's Revenue for the
three
months ended in Mar. 2026 was kr13.09 Mil. Therefore, Synthetic MR AB's EBITDA margin for the quarter that ended in Mar. 2026 was -22.44%.
Synthetic MR AB (XSAT:SYNT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Synthetic MR AB EBITDA Margin % Related Terms
Synthetic MR AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Synthetic MR AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:SYNT vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Synthetic MR AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synthetic MR AB EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Synthetic MR AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Synthetic MR AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synthetic MR AB (XSAT:SYNT) has a EBITDA Margin % of -22.44% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Synthetic MR AB and its competitors. According to the industry distribution chart, Synthetic MR AB ranks #595 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 89.6%.
Is Synthetic MR AB's EBITDA Margin % too high?
Synthetic MR AB's current EBITDA Margin % is -22.44%. Based on the distribution chart, Synthetic MR AB ranks #595 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Synthetic MR AB has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Synthetic MR AB's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Synthetic MR AB ranks #595 out of 664 companies for EBITDA Margin %. This places Synthetic MR AB in the lower half of its industry. The industry median EBITDA Margin % is 10.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Synthetic MR AB and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synthetic MR AB's current EBITDA Margin % is -22.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synthetic MR AB stock overvalued right now?
Based on GuruFocus' analysis, Synthetic MR AB (XSAT:SYNT) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.59, compared to a current price of kr0.62 — trading 86.6% below its estimated fair value. The current EBITDA Margin % is -22.44%. Synthetic MR AB's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Synthetic MR AB (XSAT:SYNT), the current EBITDA Margin % is -22.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synthetic MR AB (XSAT:SYNT) Overvalued in 2026?
Based on GuruFocus' analysis, Synthetic MR AB stock appears to be undervalued.
The current stock price of kr0.62 is trading 86.6% below its estimated GF Value™ of kr4.59.
GuruFocus considers Synthetic MR AB to be Possible Value Trap.
Key valuation signals for XSAT:SYNT:
EBITDA Margin %: -22.44%
GF Value™: kr4.59 vs. price of kr0.62 (86.6% below fair value)
No single metric tells the full story. See the XSAT:SYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synthetic MR AB develops and markets software solutions that improve the efficiency of neuroimaging processes and diagnostic accuracy. SyntheticMR's SyMRI solution measures the brain's absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single rapid examination. Combinostics offers the AI-driven cNeuro product family, which helps clinicians make a difference in the lives of patients with neurological diseases. Geographically, the group operates in America, Europe, and APAC. The majority of its revenue is generated from Europe.
63GF Score
Get the complete analysis for XSAT:SYNT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:SYNT has been successfully added to your 
